



Name: DoB:

Hospital number:

CHI:

Multi Disciplinary Care Pathway for

STAGGERED PARACETAMOL OVERDOSE

(Repeated doses taken over more than 1 hour, in the context of self-harm)

This care pathway includes the <u>ADULT</u> SNAP based regimen for acetylcysteine and is **ONLY** for use in <u>NHS LOTHIAN</u>

For advice contact the on-call toxicologist at the RIE (Monday – Friday 8.30 am – 6 pm) or the National Poisons information Service Tel 0344 892 0111 (out of hours)

Multi Disciplinary Care Pathway for	Patient Label, or
STAGGERED PARACETAMOL OVERDOSE	Name:
Date:	DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	NUIO L aditan

NHS Lothian

To be initiated once a PARACETAMOL overdose is suspected Staggered overdose

(Repeated doses ingested over more than one hour, in the context of self-harm)

KEY TO INITIALS OF <u>ALL</u> STAFF COMPLETING THIS CARE PATHWAY				
Print name	Designation	Initials	Signature	Date
1				
2				
3				
4				
5				
6				
7				

PATIENT: This document is a supplement to your record of treatment for an admission with a

suspected or confirmed paracetamol overdose.

STAFF: Should be completed in addition to the Inpatient Record (nursing admission, medical

clerking, Toxicology Questionnaire), NEWS observation chart, ED shock chart, Infusion charts and Prescription & Administration Record.

SUMMARY			Initials & time
Ingestion date(s)	Was par	acetamol bought for overdose: Yes	No □
Ingestion time(s)		racetamol ingested4 hour period)	g
Last ingestion date/time	Patient's	weight	kg
List all the drug(s) ingested	The amo	_ATE ount of paracetamol ingested	mg / kg
	Notes	For obese patients weighing more than toxic dose in mg/kg should be calculated urather than the patient's actual weight. For pregnant patients the toxic dose in more be calculated using the patient's pre-pregnant patient	using 110 kg, ng/kg should
Alcohol ingested? Yes □ No □	There is	a dosage calculator on TOXBASE® for calcu	ulating mg/kg.

Please tick boxes as appropriate and initial / time in conjunction with the Inpatient record

Multi Disciplinary Care Pathway for STAGGERED PARACETAMOL OVERDOSE Date:	Patient Label, or Name: DoB:	
Hospital: RIE □ SJH □ WGH □	Hospital number:	
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:	
	NHS Lothiar	n
STAGE 1 - IMMEDIATE ASSESSMENT AN	ND MANAGEMENT	
Staggered overdose (excessive amounts of paracetamol inchour, in the context of self-harm). Ingestion of a licensed dose not an overdose In cases of uncertainty about risk from staggered overdose disc	(e.g. in adults 4 g in a 24 hour period) is	
Monday-Friday 8.30 am - 6 pm or the National Poisons Information S	Service(NPIS) out of hours Tel 0344 892 011	
Assessment for risk of liver damage Paracetamol ingestedmg/kg (see ca	,	
Last ingestion datetimetime		
START ACETYLCYSTEINE (Refer to SNAP based dosage table on paper patients in whom there is a strong clinical suspicion of a strong overdose. (serious toxicity may occur in patients ingesting >150mg/k rarely toxicity may occur in patients ingesting between 75 hour period)	taggered paracetamol g in any 24 hour period,	
 Obtain blood samples at least 4 hours after the last par paracetamol concentration, U&Es, TCO₂, LFTs, FBC ar 		
 Clinically significant hepatotoxicity is unlikely if at let the most recent paracetamol ingestion: the paracetamol concentration is less than 10 mg the ALT is within the normal range (50 UL or less) the INR is 1.3 or less, AND the patient has no symptoms suggesting liver danger 	east 4 hours or more after /L, AND), AND	
Acetylcysteine can be discontinued if ALL the above cri	_	
 Acetylcysteine should be continued or started if any of the 		
Haemodialysis may be indicated alongside acetylcysteine if a p concentration greater than with elevated lactate. For advice cor 892 0111 out of hours	patient has a very high paracetamol	
Assessment of renal function If creatinine normal and the patient is not considered to significant liver damage no further action is required If creatinine abnormal and the patient is not considered significant liver damage, acetylcysteine may be discontible managed conventionally, and may need monitoring and may need monitoring.	to be at risk of clinically inued and the patient should	
Medical staff of grade FY2 or above must review blood real Results reviewed by	esults prior to discontinuing therapy	
If acetylcysteine is not indicated or discontinued and further bloom	od sampling is not required, go to Stage 4	

If acetylcysteine is not indicated or discontinued and further blood sampling is not required, go to Stage 4 'Subsequent Management & Discharge' [page 8]

Multi Disciplinary Care Pathway for	Patient Label, or
STAGGERED PARACETAMOL OVERDOSE	Name:
Date:	DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	l .

NHS Lothian

If you complete an entry on this page, initial as you complete each aspect of care then complete the 'KEY TO INITIALS' table on page 1 sign/print/designation.

Assessment blood results Date/Time of sample	Repeat blood results (if required) Date/Time of sample
Urea	Urea
Sodium	Sodium
Potassium	Potassium
TCO ₂	TCO ₂
Creatinine	Creatinine
eGFR	eGFR
Bilirubin	Bilirubin
ALT	ALT
Alk Phos	Alk Phos
Hb	Hb
MCV	MCV
WCC	WCC
Platelets	Platelets
INR	INR
Paracetamol concentrationmg/Lhours after last ingestion	Paracetamol concentrationmg/Lhours after last ingestion
Other	Other
Initials date / time	Initials date / time

Multi Disciplinary Care Pathway for			Patient Label, or						
	STAGGERED PARACETAMOL OVERDOSE					Name:			
Date:					DoB: Hospital num	hor			
-	I: RIE 🗆 SJH 🗖 V				CHI:	ibei	•		
Clinical	inical area: ED/A&E □ AMU □ MAU □ Obs Wa			ard □	J 51				
					N	NHS Loth	ian		
STAGE 2 – INITIATION OF TREATMENT WITH ACETYLCYSTEINE									
FOR OBESE PATIENTS WEIGHING more than 110 kg Calculate acetylcysteine dose using 110 kg rather than the patient's actual weight FOR PREGNANT PATIENTS Calculate acetylcysteine dose using the patient's actual pregnant weight									
		<u> </u>		· · · · · · · · · · · · · · · · · · ·	<u> </u>				
	THIS	SNAP BASED DOS			NLY FOR USE IN	V			
			IS LOT	HIAN e prescripti	on				
		(each ampoule =	-						
				, mr acetylc					
	Regimen	First Inf			Second				
	Infusion fluid	200 mL 5% g			1000 mL 5%	_			
	Sodium chloride 0.99 Duration of infusion 2 hours			70	sodium chloride 0.9% 10 hours				
	Drug dose	100 mg/kg ac		eine	200 mg/kg acetylcysteine				
	Patient Weight ²	Ampoule volume ³		ion Rate	Ampoule volume ³				
	kg	mL	m	ıL/h	mL		mL/h	1	
	30-39	18	1	109	35		104		
	40-49	23	1	112	45		105		
	50-59	28	1	114	55		106		
	60-69	33	1	L17	65		107		
	70-79	38	1	119	75		108		
	80-89	43	1	122	85		109		
	90-99	48	1	L 2 4	95		110		
	100-109	53	1	L 27	105		111		
	≥110	55	1	L 2 8	110		111		
	¹ Check capillary blood g	lucose at least once in al	ll patients	, and 4-hourly	in patients with dial	oetes	3		
	² Dose calculations are b	pased on the weight in the	e middle (of each band					
	³ Ampoule volume has b	een rounded up to the ne	arest wh	ole number.					
	Extended treatment - c	ontinue acetylcysteine	at the do	se and infus	ion rate used in the	2 nd	treatment bag		
Patient's	s weight	kg							
Prescript	tion and Administration	on record completed	I 🗌						
Date/tin	ne treatment com	menced				In	itial		
REACT	ION to acetylcyste	eine		COMPLI	CATIONS of p	ara	cetamol ing	estion	
None		Wheeze		Abnormal	liver function		Encephalopath	ıy	
Flushing		Hypotension		Acute kidn			Haemorrhage		
None		Wheeze		Abnormal	liver function ey injury		Encephalopath		

Acidosis

Date and time of complication

Specify.....

Initial

Rash/Itch

Date and time of reaction

Specify.....

Initial

Multi Disciplinary Care Pathway for	Patient Label, or
STAGGERED PARACETAMOL OVERDOSE	Name:
Date:	DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	NHS Lothian

STAGE 3 – END OF TREATMENT WITH ACETYLCYSTEINE

• End bag 2 blood samples
U&Es, TCO2, LFTs, FBC, INR & PARACETAMOL CONCENTRATION

• End of bag 2 blood results - documented in table below

Blood results							
	Admission Bloods	End of bag 2 bloods	End of extended bag 1 bloods	End of extended bag 2 bloods	End of extended bag 3 bloods		
Notes	* Copy from page 4	Obtain blood samples at the end of bag 2	Obtain blood samples at the end of extended bag 1	Obtain blood samples at the end of extended bag 2	Obtain blood samples at the end of extended bag 3		
		Date/time taken	Date/time taken	Date/time taken	Date/time taken		
		Initial	Initial	Initial	Initial		
Urea							
Sodium							
Potassium	*						
TCO ₂							
Creatinine	*						
eGFR							
Bilirubin							
ALT	*						
Alk. Phos							
Hb							
WCC							
Platelets							
INR	*						
Paracetamol	*						
Reviewed by		Initial	Initial	Initial	Initial		
Decision		Continue / stop	Continue / stop	Continue / stop	Continue / stop		

END OF BAG 2 bloods review:

• Criteria for DISCONTINUING acetylcysteine after Bag 2 are:

ALT is less than 50 U/L AND

ALT is less than double the admission measurement (even within normal range) AND

PARACETAMOL concentration is less than 10 mg/L

• If criteria are NOT met continue with extended acetylcysteine

*Patients with isolated INR rise of less than 0.5

For patients who have an isolated INR rise of less than 0.5, stop acetylcysteine and recheck INR and ALT after 4-6 hours.

• Criteria for DISCONTINUING acetylcysteine at this point are:

INR is unchanged or falling AND

ALT is less than 50 U/L

• If criteria not met - restart acetylcysteine at the dose and infusion rate of the last treatment bag.

If creatinine is abnormal or is 10% greater than at presentation, further acetylcysteine is not required but renal function should be monitored as an inpatient. Re-check 12 hours later.

Multi Disciplinary Care Pathway for STAGGERED PARACETAMOL OVERDOSE	Patient Label, or Name:			
Date:	DoB:			
	Hospital number:			
Hospital: RIE SJH WGH	CHI:			
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □		<u> </u>	41.1	
	NH		othian	
 End of bag 2 blood results reviewed by medical staff (of grade FY2 and above) Decision to discontinue or continue acetylcysteine documented in the table above and on page 7 				
STAGE 3 – END OF TREATMENT WITH	<u>ACETYLCYSTEINE</u>			
If criteria for discontinuing acetylcysteine at end of Bag 2	are met·		Initial	
Discontinue acetylcysteine. Time infusion discontinued				
Decision			Initial	
 If further treatment or blood sampling is not required go to Sta 	age 4 'Subsequent		& time	
Management & Discharge'(page 8) If monitoring of renal function is required obtain blood sample	es 12 hours later followed by			
a medical reviewIf extended acetylcysteine is indicated follow advice below	ow			
			Initial	
If criteria for discontinuing acetylcysteine at the end of Bag 2 are NOT met:				
Continue extended acetylcysteine treatment at the dose and infusion rate of bag 2 (page 5)			ļ	
 Obtain blood samples for U&Es, TCO₂, LFTs, FBC & INR at the end of extended bag 1 				
End of Extended bag 1 bloods review:				
Criteria for DISCONTINUING acetylcysteine after extended bag	1 are:			
INR is 1.3 or less and has not risen by 0.5 or more from adr	mission measurement* AND			
ALT is less than two times the upper limit of normal (less that	an 100 U/L) AND			
ALT is less than double the admission measurement				
• If the criteria for discontinuing are NOT met continue with furth	ner extended acetylcysteine			
If creatinine is abnormal or is 10% greater than at presentation, further function should be monitored as an inpatient. Re-check 12 hours late		ren	al	
*Patients with isolated INR rise of less than 0.5				
For patients who have an isolated INR rise of less than 0.5, stop acet 6 hours.	ylcysteine and recheck INR and AL	.T af	ter 4-	
Criteria for DISCONTINUING acetylcysteine at this point are:				
INR is unchanged or falling AND				
ALT is less than two times the upper limit of normal (less than	100 U/L)			
Otherwise commence 2 nd extended bag of acetylcysteine	. 100 0,2,			
End of extended bag 1 blood results reviewed by medical st	aff (of grade FY2 and above)		Initial & time	
 Decision to discontinue or continue acetylcysteine document and in the decision box below 	nented in the table on page 6			
Decision			Initial	
 If further treatment or blood sampling is not required go to Stage Discharge'(page 8) 	4 'Subsequent Management &		& time	
If renal function monitoring is required obtain samples 12 hours If further extended acetylcysteine is indicated follow advice				

Multi Disciplinary Care Pathway for STAGGERED PARACETAMOL OVERDOSE	Name:	Patient I	Label,	or	
Date:	DoB:				
	Hospital num	ber			
Hospital: RIE SJH WGH WGH THE STATE OF THE STAT	CHI:				
Clinical area: ED/A&E ☐ AMU ☐ MAU ☐ Obs Ward ☐	O				
				NHS	Lothian
If further extended treatment is required:	<u> </u>				Initial & time
• Continue acetylcysteine at the dose and infusion rate used in the 2	2 nd treatment b	ag (Page	5)]
• Ward level capillary blood glucose monitoring (BMs) at least four ti	mes daily]
Recheck U&Es, LFTs, FBC and INR every 9 hours to assess the company of the c	ourse of liver	injury (1 h	our		_
before the end of each extended bag). Document results on page		, , ,]
Discontinue further extended treatment when:					
INR 1.3 or less; OR falling towards normal on two consecutive blocks.	ood tests, and	less than 3	3.		
There is no clinical advantage to treating ALT rises after this norm				oratio	n of
hepatic synthetic function)					
Extended treatment with acetylcysteine was required If YES, number of extended bags required	Ye	es 🗆	١	No □	Initial & time
Once treatment with acetylcysteine is discontinued and further bl	and tasts are	not requir	od ao	to Sta	70. 4
'Subsequent Management & Dischar		not requir	eu go	.o Sta	y c 4
	3 (1 3 -7				
STAGE 4 – SUBSEQUENT MANAGEME	NT & DISCH	ARGE			
<u> </u>					Initial/time
Target					
Treatment with acetylcysteine tolerated	N/A □	Yes □	No		
Patient eating and drinking.		Yes □	No		
Seen by Psychiatry team member	N/A □	Yes □	No		
Comment					
					luciti a l/tima
Discharge					Initial/time
Treatment complete	N/A □	Yes □	No		
Criteria for discharge met	14// =	Yes □	No		
Comment					
Discharge advice given, including paracetamol patient disc	narge sneet				
(available on TOXBASE®)					
NOK informed		Yes □	No		
Comment					
Left department Date Time Time					
					Initial/time
Follow-up	NI/A 🖂	V □	NI.		
 Has follow-up been arranged? 	N/A □	Yes □	No		
Comment					
Notes Medical follow-up arrangements are not normally required if	blood results	are within	accep	table	ange